Guggenheim Maintains Buy on Travere Therapeutics, Lowers Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Vamil Divan has maintained a 'Buy' rating on Travere Therapeutics (NASDAQ:TVTX), but lowered the price target from $25 to $18.
September 22, 2023 | 3:51 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Guggenheim has maintained a 'Buy' rating on Travere Therapeutics but lowered the price target from $25 to $18.
The news is directly related to Travere Therapeutics. While the 'Buy' rating is maintained, the lowering of the price target could indicate a potential decrease in the short-term stock price. However, the impact is not necessarily negative as the 'Buy' rating is still in place.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100